Long-term Beta-blocker Therapy After Acute Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2026-03-20
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine whether discontinuation of β-blocker after at least 1
year of β-blocker therapy is noninferior to continuation of β-blocker in patients without
heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction
(AMI).
Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether
discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to
continuation of β-blocker in patients without HF or left ventricular systolic dysfunction
after AMI.
Phase:
Phase 4
Details
Lead Sponsor:
Samsung Medical Center
Collaborators:
Chonbuk National University Hospital Chonnam National University Hospital Chosun University Hospital Chungbuk National University Hospital Chungnam National University Hospital Ewha Womans University Ewha Womans University Seoul Hospital Gyeongsang National University Hospital Inje University Jeju National University Hospital Kangbuk Samsung Hospital Keimyung University Dongsan Medical Center Korea University Anam Hospital Kyung Hee University Hospital Presbyterian medical center Saint Vincent's Hospital, Korea Samsung Changwon Hospital Sejong General Hospital Seoul National University Bundang Hospital Wonju Severance Christian Hospital Wonkwang University Hospital